ArticleScience advances2020
Gadofullerene inhibits the degradation of apolipoprotein B100 and boosts triglyceride transport for reversing hepatic steatosis.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 66 citations in OpenAlex.
- LLMs uncover 6M1@C60's therapeutic targets: inhibiting atherosclerotic progression via NRF2/HO-1/GPX4 axis-mediated ferroptosis suppression.Journal of nanobiotechnology · 2026Article
- Nanomedicines Against Mitochondrial Dysfunction-Induced Metabolic Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Gut symbiont-derived ursodeoxycholic acid promotes fatty acid oxidation to protect against renal ischemia-reperfusion injury.Cell reports. Medicine · 2025Article
- A charge reversal nano-assembly prevents hepatic steatosis by resolving inflammation and improving lipid metabolism.Bioactive materials · 2025Article
- Curdlan-Decorated Fullerenes Mitigate Immune-Mediated Hepatic Injury for Autoimmune Hepatitis Therapeutics via Reducing Macrophage Infiltration.ACS applied materials & interfaces · 2024Article
- Recovering intestinal redox homeostasis to resolve systemic inflammation for preventing remote myocardial injury by oral fullerenes.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Oral nano-antioxidants improve sleep by restoring intestinal barrier integrity and preventing systemic inflammation.National science review · 2023Article
- Fumigaclavine C ameliorates liver steatosis by attenuating hepatic de novo lipogenesis via modulation of the RhoA/ROCK signaling pathway.BMC complementary medicine and therapies · 2023Article
- Theoretical Study on a Supramolecular Dimeric Structure Constructed by Metallofullerene YACS omega · 2023Article
- Delivery of miR-3529-3p using MnOThoracic cancer · 2023Article
- Proteomics and transcriptomics profiling reveals distinct aspects of kidney stone related genes in calculi rats.BMC genomics · 2023Article
- Self-driven carbon atom implantation into fullerene embedding metal-carbon cluster.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Progress in Antiviral Fullerene Research.Nanomaterials (Basel, Switzerland) · 2022Review
- Fullerene nanoparticles for the treatment of ulcerative colitis.Science China. Life sciences · 2022Article
- CNanoscale · 2022Article
- Creatine modulates cellular energy metabolism and protects against cancer cachexia-associated muscle wasting.Frontiers in pharmacology · 2022Article
- Hepatitis C virus induces oxidation and degradation of apolipoprotein B to enhance lipid accumulation and promote viral production.PLoS pathogens · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic steatosis is a widespread metabolic disease characterized by excessive accumulation of triglyceride (TG) in liver. So far, effective approved drugs for hepatic steatosis are still in development, and removing the unnecessary TG from the hepatocytes is an enormous challenge. Here, we explore a promising anti-hepatic steatosis strategy by boosting hepatocellular TG transport using β-alanine-modified gadofullerene (GF-Ala) nanoparticles. We confirm that GF-Ala could reverse hepatic steatosis in oleic acid-induced hepatocytes, fructose-induced mice, and obesity-associated transgenic
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.